gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SEPNHealthcarePharmaceuticals

Septerna, Inc. Common Stock (SEPN)

$47.88+9.57%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$47.29▲ 135.86% in range
Nov 3, 2025Low $18.10 · High $48.19Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Septerna closed at $47.88 on Nov 4, up 9.57%, 0.6% below its 52-week closing high. Volume of 605.3K shares was 1.64× its 20-day average (above normal).

Split-adjusted performance: +34.2% over one month, +93.8% over six months, +138.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $26.75M, up 22375.6% from a year earlier, with a net margin of -48.7%.

Short interest was 3.5M shares at the Oct 15 settlement, up 13.8% from the prior report (12.0% of float, 7.6 days to cover).

Market cap$2.23B46.7M shares
Revenue · quarter$26.7M+22375.6% YoY
Diluted EPS$-0.29—
P/E · TTM—P/S 22.6×
Net margin-48.7%Gross 100.0%
Dividend yieldNone
52-week range18.10 – 48.19−0.6% from high
Volume605.3K1.64× 20-day avg
Volatility · 60d49.1%Annualised
Short % of float12.0%7.6 days to cover
Net cash$372.3MCash $372.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.2%1M +34.2%3M +21.1%6M +93.8%YTD +71.7%1Y +138.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum98
Revenue growth100
Net margin45
Value (low P/E)—
Size83

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.5M+13.8% vs prior
Days to cover7.6Settled Oct 15
% of float12.0%
Short vol. 10d71.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SEPNSepterna$47.88+9.57%+93.8%+22375.6%−48.7%—$2.23B
TRLVTrulieve Cannabis$11.60+0.52%——−149.8%—$2.23BCompare
ZYMEZymeworks$30.94+2.69%+12.1%−90.6%−980.8%—$2.22BCompare
PRGOPERRIGO$15.83+0.83%+29.1%−3.2%7.3%—$2.20BCompare
AUPHAurinia Pharmaceuticals$17.11+3.32%+5.3%+13.9%37.9%7.3$2.29BCompare
BHVNBiohaven$15.24−2.37%+51.8%———$2.30BCompare
IMNMImmunome$19.52−3.89%−16.1%−100.0%——$2.30BCompare
VERAVera Therapeutics$31.97+4.10%−12.6%———$2.30BCompare
PVLAPalvella Therapeutics$162.28+6.11%+24.7%———$2.34BCompare

News about Septerna

All news →
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Sep 10, 2026▲ PositiveSepterna to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 1, 2026▲ PositiveSepterna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?The Motley Fool · Jul 5, 2026NeutralIs Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?The Motley Fool · Jun 30, 2026NeutralSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategyGlobeNewswire Inc. · Mar 1, 2026▲ Positive

Quick answers

What does Septerna do?
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies.
What is SEPN's market cap?
$2.23B, based on the Nov 4 close of $47.88.
Does Septerna pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SEPN is sold short?
3.5M shares, 12.0% of float, as of Oct 15, 2026.
What sector is SEPN in?
Healthcare, in the Pharmaceuticals industry.

About Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

HQ: South San Francisco, CA130 employeesListed Oct 25, 2024septerna.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology